{"corpus_id":13697518,"paper_sha":"32604cbb316a549e545ee5a8232e6a8ef19b573b","doi":"10.1186/s13023-018-0815-5","arxiv_id":null,"pmid":29728119,"pmcid":"5935942","mag_id":2799963223,"dblp_id":null,"acl_id":null,"title":"Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies","year":2018,"publication_date":"2018-05-04","venue":"Orphanet Journal of Rare Diseases","journal":{"name":"Orphanet Journal of Rare Diseases","pages":null,"volume":"13"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","Review"],"pubmed_pub_types":["Journal Article","Systematic Review"],"s2_fields_of_study":["Medicine"],"reference_count":41,"citation_count":150,"influential_citation_count":7,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Angioedema","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"epidemiology","mj":true,"ui":"Q000453"},{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D000799"},{"d":"Angioedemas, Hereditary","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"epidemiology","mj":false,"ui":"Q000453"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D054179"},{"d":"Angiotensin-Converting Enzyme Inhibitors","mj":false,"qs":[{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D000806"},{"d":"Bradykinin","mj":false,"qs":[{"q":"metabolism","mj":true,"ui":"Q000378"}],"ui":"D001920"},{"d":"Epidemiologic Studies","mj":false,"ui":"D016021"},{"d":"Humans","mj":false,"ui":"D006801"}],"chemicals":[{"n":"Angiotensin-Converting Enzyme Inhibitors","ui":"D000806","reg":"0"},{"n":"Bradykinin","ui":"D001920","reg":"S8TIM42R2W"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-018-0815-5","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/32604cbb316a549e545ee5a8232e6a8ef19b573b","s2_open_access_license":"CCBY","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BackgroundBradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific targeted therapies. Knowledge of its epidemiology may help optimize its management.MethodsWe systematically searched the medical literature to identify abstracts of interest indexed between 1948 and March, 2016. We used published national survey data on the proportion of the population treated with angiotensin-converting enzyme inhibitors (ACEI) to derive estimates of the population prevalence of ACEI-AE in the USA, Germany and France. For hereditary angioedema (C1-INH-HAE) and C1-inhibitor related acquired angioedema (C1-INH-AAE), publications had to contain original epidemiologic data collection within a defined geographical area. Hereditary angioedema with normal C1-INH was not included in the analysis due to lack of clearly defined criteria.ResultsWe identified 4 relevant publications on the prevalence of ACEI-AE, 6 on the prevalence of C1-INH-HAE, and 1 on the prevalence of C1-INH-AAE. The 1st year cumulative incidence of ACEI-AE was estimated to vary between 0.12 (population-based analyses) and 0.30 (meta-analyses of clinical trials) per 100 patient-years. The population prevalence of ACEI-AE was modeled to vary between 7 and 26 in 100,000. The prevalence of C1-INH-HAE was estimated to vary between 1.1 and 1.6 per 100,000. The prevalence of C1-INH-AAE was estimated to be 0.15 per 100,000 in one epidemiological investigation of AAE in Denmark.ConclusionsEpidemiological evidence on Bk-AE is limited to North America and Europe. ACEI-AE is more common than C1-INH-HAE (~ 10:1), which is more common than C1-INH-AAE (~ 10:1). More studies are needed to comprehensively assess the epidemiological burden of Bk-AE.","claims":[{"public_id":"cl_7bbc52afa35f0363e4827751efe2be0c","status":"active","text":"Angiotensin-converting enzyme inhibitor-associated angioedema is more common than hereditary angioedema with C1 inhibitor deficiency by about 10:1, and hereditary angioedema with C1 inhibitor deficiency is more common than C1-inhibitor related acquired angioedema by about 10:1.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_7bbc52afa35f0363e4827751efe2be0c"},{"public_id":"cl_5025bc53837cfad91c868bbf036e2749","status":"active","text":"Epidemiological evidence on bradykinin-mediated angioedema is limited to North America and Europe.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5025bc53837cfad91c868bbf036e2749"},{"public_id":"cl_9bb7983d98a9a88e0c081deb0de57e43","status":"active","text":"Hereditary angioedema with C1 inhibitor deficiency is estimated to have a prevalence of 1.1 to 1.6 per 100,000, while C1-inhibitor related acquired angioedema is estimated at 0.15 per 100,000 in the Danish epidemiological investigation.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_9bb7983d98a9a88e0c081deb0de57e43"},{"public_id":"cl_8a8f703f9df9ed6272c9604895080dcc","status":"active","text":"The first-year cumulative incidence of angiotensin-converting enzyme inhibitor-associated angioedema varies between 0.12 and 0.30 per 100 patient-years.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_8a8f703f9df9ed6272c9604895080dcc"},{"public_id":"cl_4d0258db1db26c5062ffc0908502f12c","status":"active","text":"The population prevalence of angiotensin-converting enzyme inhibitor-associated angioedema is modeled to vary between 7 and 26 per 100,000.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4d0258db1db26c5062ffc0908502f12c"}],"concepts":[{"public_id":"co_2fcd859cdd5086e9462580a380166a73","status":"active","name":"100,000","description":"A population-rate denominator expressed per one hundred thousand people.","types":["unit"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_2fcd859cdd5086e9462580a380166a73"},{"public_id":"co_7319c66663f901af3c55c8076089e1af","status":"active","name":"North America and Europe","description":"The geographic regions covered by the identified epidemiological studies.","types":["geographic region"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7319c66663f901af3c55c8076089e1af"},{"public_id":"co_7ab47c1a87701efe8a82d411620eafb5","status":"active","name":"angiotensin-converting enzyme inhibitor-associated angioedema","description":"Angioedema associated with treatment using angiotensin-converting enzyme inhibitors.","types":["condition"],"aliases":["ACEI-AE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7ab47c1a87701efe8a82d411620eafb5"},{"public_id":"co_7eaf7808a055def3c037d37eef8a9405","status":"active","name":"bradykinin-mediated angioedema","description":"A form of angioedema driven by bradykinin rather than histamine.","types":["condition"],"aliases":["Bk-AE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7eaf7808a055def3c037d37eef8a9405"},{"public_id":"co_8d515ab34e5794327c301eb5bb947977","status":"active","name":"100 patient-years","description":"A rate denominator expressing events per one hundred patient-years of observation.","types":["unit"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8d515ab34e5794327c301eb5bb947977"},{"public_id":"co_b1ffb72868a95fe010b51e5d50f2dc99","status":"active","name":"epidemiological evidence","description":"Population-based data on the occurrence of disease across regions and study designs.","types":["evidence"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b1ffb72868a95fe010b51e5d50f2dc99"},{"public_id":"co_c276b059e57980bc83d0463a5f4480e4","status":"active","name":"population prevalence","description":"The proportion of a population affected by a condition at a given time or over a defined period.","types":["epidemiological measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c276b059e57980bc83d0463a5f4480e4"},{"public_id":"co_ca8ffcea2133ce29e3266bedc92803be","status":"active","name":"hereditary angioedema with C1-INH deficiency","description":"A hereditary angioedema subtype caused by deficiency or dysfunction of C1 inhibitor.","types":["condition"],"aliases":["C1-INH-HAE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ca8ffcea2133ce29e3266bedc92803be"},{"public_id":"co_cb71314bd1d6a6d81aff9fd0da7902ee","status":"active","name":"first-year cumulative incidence","description":"The accumulated occurrence of new cases during the first year of follow-up.","types":["epidemiological measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cb71314bd1d6a6d81aff9fd0da7902ee"},{"public_id":"co_d4564120aab5daa2469c81e5d21a1d9b","status":"active","name":"prevalence","description":"The number or proportion of existing cases in a population.","types":["epidemiological measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d4564120aab5daa2469c81e5d21a1d9b"},{"public_id":"co_fd02723014a907890ec549603d2dcdc1","status":"active","name":"C1-inhibitor related acquired angioedema","description":"An acquired angioedema subtype related to abnormalities of C1 inhibitor.","types":["condition"],"aliases":["C1-INH-AAE"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_fd02723014a907890ec549603d2dcdc1"}],"external_ids":{"DOI":"10.1186/s13023-018-0815-5","ArXiv":null,"PubMed":29728119,"PubMedCentral":"5935942","MAG":2799963223,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-018-0815-5","landing_url":"https://www.semanticscholar.org/paper/32604cbb316a549e545ee5a8232e6a8ef19b573b","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631945,"paper_uid":"d32a4aaf-098c-48ed-86ae-f7569e7911d4","canonical_identity":{"paper_id":631945,"paper_uid":"d32a4aaf-098c-48ed-86ae-f7569e7911d4","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/13697518"}